Skip to main content
Premium Trial:

Request an Annual Quote

Manuel Hidalgo and David Bramhill

Premium
Champions Biotechnology, a nascent biotech company based in Arlington, Va, this week announced the appointment of Manuel Hidalgo as a company director and scientific advisor. Hildago will advise and assist the company in the development of benzoylphenylurea sulfur analog compounds and the human cancer xenograft platform that the company recently acquired.
 
Hidalgo will also advise Champions Biotechnology on future therapeutic drug candidates and technologies that it intends to acquire. He will assist the company in the formation of its scientific advisory board.
 
Hidalgo is currently an associate professor of oncology at the Sidney Kimmel Comprehensive Cancer Center in Baltimore and director of the Centro Integral Oncologia "Clara Campal" in Madrid, Spain.
 

 
Research Corporation Technologies this week announced that David Bramhill has joined the company as director of its Gene eXpression Technologies Program.
 
Bramhill is responsible for managing and supporting existing licenses and partners, and securing new users and licensees for the various GXT technologies. He also assesses novel gene expression, protein production, and protein therapeutic technologies for potential acquisition and development by RCT.
 
Bramhill was previously the founder of Bramhill Biological Consulting in Westfield, NJ. Before that, he held research and licensing positions at Merck Research Laboratories. Prior to joining Merck, he was a research fellow at Stanford University.
 
RCT is a Tucson, Ariz.-based technology investment and management company that provides early-stage funding and development for promising biomedical companies and technologies.